surufatinib + temozolomide + S-1

Surufatinib + temozolomide + S-1 is a novel combination therapy being investigated for the treatment of advanced neuroendocrine tumors (NETs). This combination leverages the unique mechanisms of each component to potentially enhance antitumor activity. It consists of: * **Surufatinib**: An oral, small-molecule tyrosine kinase inhibitor that potently inhibits VEGFR1, VEGFR2, VEGFR3, FGFR1, and CSF-1R, inhibiting tumor angiogenesis and regulating tumor-immune evasion. * **Temozolomide**: An alkylating agent that damages DNA and triggers cell death in rapidly dividing cells. * **S-1**: An oral dihydropyrimidine dehydrogenase (DPD) inhibitory fluoropyrimidine that contains tegafur (a prodrug of 5-fluorouracil), gimeracil (an inhibitor of dihydropyrimidine dehydrogenase), and potassium oxonate (an inhibitor of the phosphorylation of fluorouracil in the gastrointestinal tract).